Viromed Medical AG – Corporate Events and Regulatory Filings

Viromed Medical AG, listed on Xetra with the ticker VMDM, announced several regulatory and corporate developments on 15 January 2026. The following points summarize the key events and their implications.

1. Conversion to Registered (Named) Shares

On 15 January 2026 the company announced a transition from bearer to registered shares.

  • The conversion was scheduled to take place in the evening of 16 January 2026.
  • All existing shares will be converted on a 1:1 basis, with no change in the number of shares outstanding.
  • The conversion will affect the depository settlement system, requiring holders to register their holdings with a designated custodian.

This change aligns Viromed Medical AG with regulatory requirements that favor registered share structures for greater transparency and shareholder rights.

2. ISIN Change

Concurrently, the company implemented a new ISIN code.

  • The previous ISIN DE000A3MQR65 was withdrawn on 14 January 2026.
  • The new ISIN DE000A40ZVN7 became effective on 15 January 2026.
  • The exchange of codes was executed on a 1:1 basis, ensuring continuity for market participants.

The ISIN update is a routine procedural step associated with the share‑conversion process and does not affect the market value or the legal status of the shares.

3. Management‑Related Transaction Disclosure

On 13 January 2026, the board disclosed a transaction by Uwe Perbandt, a member of the executive board.

  • Perbandt sold shares of Fonterelli SPAC 2 on 9 January 2026, reducing his personal holding in that entity.
  • The disclosure complied with the German Securities Trading Act (WpPG) and the Securities Trading Ordinance (WpStV).
  • No conflict of interest or insider‑trading concerns were identified, as the sale was executed outside any restricted period.

The disclosure demonstrates Viromed Medical AG’s adherence to regulatory requirements for the public announcement of significant transactions by key personnel.

4. Strategic Milestone for PulmoPlas

The company released a strategy update on 8 January 2026, highlighting a forthcoming milestone for its PulmoPlas platform, which delivers cold atmospheric plasma (CAP) therapy.

  • PulmoPlas is a core product line within Viromed’s portfolio, targeting pulmonary and wound‑care applications.
  • The announced milestone is a regulatory or clinical development expected to enhance market acceptance and commercial prospects.
  • While specific dates and outcomes were not disclosed, the update signals continued investment in the technology and its potential to expand the company’s product offerings.

5. Market Context

  • As of 13 January 2026, Viromed Medical AG’s share price closed at €4.08.
  • The 52‑week high and low were €5.70 and €1.50, respectively, indicating a relatively stable trading range.
  • The company’s market capitalization stood at approximately €67.6 million.

The share conversion, ISIN update, and management disclosure are routine procedural matters that collectively reinforce the company’s governance and regulatory compliance. The strategic update for PulmoPlas suggests an ongoing focus on product development and potential future revenue growth.